17 results about "Warfarin" patented technology

The present invention relates to a liquid, multi-dose, ready-to-use pharmaceutical composition comprising: a) warfarin or a pharmaceutically acceptable salt thereof, b) an excipient that is both an antioxidant and pH regulator, and c) a fluid; wherein the composition has a pH of 8.0 – 11.0. The invention further provides a method of manufacturing said pharmaceutical warfarin composition and provides uses of the pharmaceutical warfarin composition.

This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

The present invention provides an anticoagulant reversal agent which is a compound having the structure represented by formula I, a salt thereof, or a deuterated thereof. Experimental results have shown that the compound according to the present invention can more effectively suppress hemorrhagic complications caused by anticoagulants such as warfarin, heparin, and enoxaparin sodium, and exhibits high efficacy over a broad spectrum.

A hollow multilayer MOF material and its preparation method and application relates to the field of nano drug delivery therapy technology. A ZIF-67@ZIF-8@ZIF-67@ZIF-8 hollow multilayer MOF material is applied as a thrombus drug nanocarrier to prepare drugs for thrombus treatment. In vitro experiments indicate that the thrombus drug nanocarrier has an efficient targeting effect and an excellent sustained release effect in combination with streptokinase and warfarin, and the thrombus drug nanocarrier has a good therapeutic effect and the long-term anticoagulant effect.

This invention discloses a chiral covalent organic framework composite membrane prepared by in-situ growth and its applications. This invention uses [NALC] as a reference. X -TAPB-DVA COF S As a functionalized material, a chiral covalent organic framework composite membrane was prepared by a secondary in-situ growth method using terephthalaldehyde (PAD) as the linker and 1,3,5-tris(4-aminophenyl)benzene (TAPB) as the nucleation site. This chiral covalent organic framework composite membrane can resolve enantiomers of mandelic acid, warfarin, naproxen, and ibuprofen, exhibiting a wide resolution range and stable resolution performance.

According to the anticoagulant venous catheter and the preparation method thereof provided by the invention, a multi-element complex synthesized by three substances of rare earth chloride, warfarin and salicylic acid and PVC resin are subjected to extrusion forming together, and the catheter capable of meeting the use requirements of external anticoagulant instruments is obtained. Wherein the multi-element complex destroys a normal blood coagulation process by influencing a protein structure and an expression process in blood, so that an anticoagulation effect is achieved.

The invention relates to the technical field of warfarin dose regulation and control, and discloses a warfarin dose prediction and adjustment method and system based on multiple linear regression, and the system comprises a patient data collection module, a gene data acquisition module, a model construction module, a dose adjustment module, and a real-time prediction and adjustment execution module. The patient data acquisition module synchronously acquires multi-dimensional parameters in different treatment states and establishes a treatment data set; the gene data acquisition module takes gene polymorphism and age data, a treatment data set is combined to construct a refined patient feature space, and the model construction module constructs and trains a multiple linear regression prediction model according to the refined patient feature space and extracts dose indexes; the dose adjustment module establishes a mapping relation between dose adjustment levels and dose indexes, and the real-time prediction module obtains real-time treatment parameters and obtains real-time self-adaptive dose indexes in combination with the model; the adjustment execution module obtains a predicted adjustment level according to the mapping relation, and triggers a dose adjustment mechanism if the predicted adjustment level exceeds a preset threshold.

The application relates to the technical field of warfarin dose regulation, and discloses a warfarin dose prediction adjustment method and system based on multiple linear regression, which comprises a patient data acquisition module, a gene data acquisition module, a model construction module, a dose adjustment module, a real-time prediction module and an adjustment execution module. The patient data acquisition module synchronously acquires multi-dimensional parameters under different treatment states to build a treatment data set; the gene data acquisition module acquires gene polymorphism and age data, combines the treatment data set to build a refined patient characteristic space, and the model construction module builds and trains a multiple linear regression prediction model according to the patient characteristic space to extract a dose index; the dose adjustment module builds a dose adjustment level and a mapping relationship with the dose index; the real-time prediction module acquires real-time treatment parameters, combines the model to obtain a real-time self-adaptive dose index; the adjustment execution module obtains a prediction adjustment level according to the mapping relationship, and if the prediction adjustment level exceeds a preset threshold, a dose adjustment mechanism is triggered.

The invention discloses a warfarin dose real-time decision-making method based on multi-factor dynamic analysis, and the method specifically comprises the following steps: S1, data collection: collecting basic treatment data of a patient, and carrying out the preprocessing of the basic treatment data; s2, carrying out persistent storage, serialization and deserialization on the basic treatment data; the basic treatment data is subjected to array recording according to the time sequence; and S3, based on the acquired treatment data, performing real-time warfarin dosage decision, and giving a specific warfarin medication dosage result. According to the method, pre-training is not needed, calculation and decision making can be carried out immediately after new data are received, and the method is particularly suitable for handling emergency situations and initial calculation of first-time medication.

The present invention addresses the problem of achieving an estimation system that can estimate warfarin dosage with higher accuracy. An estimation system (100) solves this problem by including an acquisition unit (12) that acquires subject information and target information, and an estimation unit (14) that estimates an estimated value using an estimation model (21) that uses at least any of subject information, target information, and subject comparison information as explanatory variables and an estimated value of warfarin dosage as a response variable.

This invention discloses an isolated anti-FXI and / or anti-FXIa antibody or its antigen-binding fragment, which specifically binds to human FXI or FXIa, and provides a drug targeting FXI that effectively prevents or treats thrombosis with minimal side effects to meet medical needs. Because currently approved anticoagulants interfere with hemostasis, leading to an increased risk of bleeding, there is a significant unmet medical need for safer anticoagulants. Although thrombosis can be treated or prevented with anticoagulants (e.g., heparin, warfarin, aspirin, or factor Xa inhibitors), these treatments have significant adverse effects. Genetic and pharmacological evidence in humans and animals suggests that lowering coagulation factor XI (FXI) can successfully prevent and manage thrombosis with minimal bleeding.

The invention discloses a medicine composition of mulberroside C and 7-hydroxywarfarin and application of the medicine composition in acute kidney injury, and belongs to the technical field of medicine development. The mulberroside C and the 7-hydroxywarfarin are combined according to the mass ratio of 1: 1, so that multiple physiological and biochemical indexes related to the acute kidney injury can be remarkably improved, and the kidney tissue structure change can be repaired; compared with single use of mulberroside C or 7-hydroxywarfarin, the combination of mulberroside C and 7-hydroxywarfarin shows an obvious synergistic effect. The pharmaceutical composition disclosed by the invention can effectively relieve acute kidney injury induced by various factors, improve kidney function indexes and reduce the injury degree of kidney tissues, so that the pharmaceutical composition has a good application prospect in prevention and treatment of the acute kidney injury, and a new treatment strategy and a potential target spot are provided for intervention of the acute kidney injury.

This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

The invention relates to a method for preparing warfarin by a microchannel reactor. The method comprises the following steps: respectively injecting a mixed solution of o-hydroxyacetophenone, PEG6000, sodium methoxide and toluene and a mixed solution of toluene and dimethyl carbonate into a micro-mixer, mixing, enabling the mixed solution to enter a first module of a micro-channel reactor for reaction, and enabling the reacted solution to flow into a second module of the micro-channel reactor; injecting a mixed solution of benzalacetone and ethanol into the second module group to react with a product flowing out of the first module group, and flowing into the third module group after the reaction; and respectively injecting a hydrochloric acid solution and ethyl acetate into the third module group to react with the intermediate product flowing out of the second module group, enabling the reacted solution to flow into an aqueous solution containing saturated sodium chloride, and performing post-treatment on an organic phase to obtain warfarin. The method has the advantages of low production cost, environmental friendliness, simple process, and high yield and purity of warfarin.

This invention discloses a method for studying the procoagulant mechanism of vitamin K1 based on nuclear magnetic resonance metabolomics. The method includes: inducing a rat bleeding model by gavage administration of warfarin, followed by intravenous injection of vitamin K1 via the tail vein; analyzing rat serum using 1H NMR to obtain the 1H NMR spectra of metabolites; screening the 1H NMR spectra of metabolites using an orthogonal partial least squares discriminant analysis model to identify potential biomarkers; performing metabolic pathway enrichment analysis on the potential biomarkers to identify relevant important metabolic pathways; and connecting the potential biomarkers within the important metabolic pathways to obtain a comprehensive metabolic network. This method provides a more comprehensive and unbiased explanation of the procoagulant mechanism of vitamin K1 at a holistic level, offering new insights for future research on the procoagulant mechanism of vitamin K1.

The invention relates to an atrial fibrillation patient intelligent management platform and management method, which combines an AI algorithm model to perform big data learning on atrial fibrillation symptom data and clinical diagnosis and treatment measures of an atrial fibrillation patient, and utilizes the model to provide symptom recognition for the atrial fibrillation patient and recommend an emergency use strategy of an atrial fibrillation drug warfarin. According to the method, the model can recommend correspondingly matched warfarin usage and dosage according to the atrial fibrillation symptoms of the atrial fibrillation patient, so that first-aid measures which can be referenced and executed are quickly provided for the atrial fibrillation patient, manual analysis is replaced, the first-aid management capability of the atrial fibrillation patient is improved, the prevention and management level of atrial fibrillation is improved, and the prevention and management efficiency is improved. The potential safety hazard caused by the fact that the atrial fibrillation patient cannot obtain the first-aid medicine is reduced.

The invention discloses a primer group and a kit for warfarin individualized medication related gene SNP (Single Nucleotide Polymorphism) detection. The primer group comprises PCR (Polymerase Chain Reaction) primers and an extension primer, wherein the PCR primers are used for detecting VKORC1rs141753512SNP (Single Nucleotide Polymorphism) sites in peripheral blood DNA (Deoxyribose Nucleic Acid), the sequences of the PCR primers are as shown in SEQ ID No.1 and SEQ ID No.2, and the sequence of the extension primer is as shown in SEQ ID No.3. The kit comprises the primer group disclosed by the invention. The kit disclosed by the invention can be used for carrying out high-throughput detection on the sites, and has the advantages of high sensitivity, high specificity, stable detection result, high reliability and the like; meanwhile, the method is suitable for gene analysis fields such as clinical disease mutation detection, pharmacogenomics analysis and forensic medicine identification.